- A study from the Departments of Medicine and Cancer Biology; and Abramson Family Cancer Research Institute, Perelman School of Medicine, Philadelphia has reported that “SPSB1 Promotes Breast Cancer Recurrence by Potentiating c-MET Signaling.”
- This study was published in the July 2014 Cancer Discovery by Prof. Lewis A. Chodosh, Feng Yi and others from the Departments of Medicine and Cancer Biology; and Abramson Family Cancer Research Institute, Perelman School of Medicine, Philadelphia.
- On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: MiRNAs-based therapeutics targeting chemotherapeutic resistance in Mammary cancers: MiRNA-199a-3p inhibits mammary cancer recurrence through suppression of the SPSB1–c-MET pathway. This study suggests that MiRNA-199a-3p, by decreasing the expression of its target gene, it could decrease mammary cancer recurrence. Taken together, this study suggests that (1) pharmacological formulations containing “MiRNA-199a-3p or its activators” can be used to decrease mammary cancer recurrence; and (2) MiRNA-199a-3p activators can be used to decrease chemotherapeutic resistance.
Idea Proposed/Formulated by: Dr L Boominathan PhD
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, MiRNAs-based therapeutics targeting chemotherapeutic resistance in mammary cancers: miR-199a-3p inhibits mammary cancer recurrence through suppression of the SPSB1–c-MET pathway, 10/July/2014, 6.17 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
Web: http://genomediscovery.org
* Research cooperation
